CGEM

Cullinan Therapeutics Stock Analysis

AI Rating

Fair
  • Quality4/10
  • Growth↓ 1/10
  • Value↑ 5/10
Cullinan Therapeutics sales and earnings growth
CGEM Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -20.86%
  • FCF Y/Y↓ -20.99%
Cullinan Therapeutics gross and profit margin trends
CGEM Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -34.72%
Cullinan Therapeutics net debt vs free cash flow
CGEM Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Cullinan Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗